EGFR monoclonal antibodies in locally advanced head and neck squamous cell carcinoma: What is their current role?

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Treatment options for locally advanced squamous cell carcinoma of the head and neck (SCCHN) include either surgical resection followed by radiation or chemoradiation, or definitive chemoradiation for which single-agent cisplatin is the best studied and established. The increasing understanding of the molecular biology of SCCHN has led to an interest in the development of targeted therapies. The epidermal growth factor receptor (EGFR) is over-expressed in nearly 80-90% of cases of SCCHN and correlates with poor prognosis and resistance to radiation. Preclinical evidence showed that blocking EGFR restores radiation sensitivity and enhances cytotoxicity. This finding led to clinical trials evaluating this class of agents and the approval of cetuximab in combination with radiation for the treatment of locally advanced SCCHN. This review is focused on the anti-EGFR monoclonal antibodies and their role either with radiotherapy or chemoradiation in unresectable LA SCCHN.

Original languageEnglish (US)
Pages (from-to)170-179
Number of pages10
JournalCritical Reviews in Oncology/Hematology
Volume99
DOIs
StatePublished - Mar 1 2016

Fingerprint

Epidermal Growth Factor Receptor
Monoclonal Antibodies
Radiation
Radiation Tolerance
Cisplatin
Molecular Biology
Radiotherapy
Therapeutics
Carcinoma, squamous cell of head and neck
Clinical Trials

Keywords

  • Anti-EGFR monoclonal antibodies
  • Cetuximab
  • Chemoradiation
  • Locally advanced head and neck cancer

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Geriatrics and Gerontology

Cite this

@article{4c350dabf9d74ce6ac9090144076c658,
title = "EGFR monoclonal antibodies in locally advanced head and neck squamous cell carcinoma: What is their current role?",
abstract = "Treatment options for locally advanced squamous cell carcinoma of the head and neck (SCCHN) include either surgical resection followed by radiation or chemoradiation, or definitive chemoradiation for which single-agent cisplatin is the best studied and established. The increasing understanding of the molecular biology of SCCHN has led to an interest in the development of targeted therapies. The epidermal growth factor receptor (EGFR) is over-expressed in nearly 80-90{\%} of cases of SCCHN and correlates with poor prognosis and resistance to radiation. Preclinical evidence showed that blocking EGFR restores radiation sensitivity and enhances cytotoxicity. This finding led to clinical trials evaluating this class of agents and the approval of cetuximab in combination with radiation for the treatment of locally advanced SCCHN. This review is focused on the anti-EGFR monoclonal antibodies and their role either with radiotherapy or chemoradiation in unresectable LA SCCHN.",
keywords = "Anti-EGFR monoclonal antibodies, Cetuximab, Chemoradiation, Locally advanced head and neck cancer",
author = "Mohamed Alorabi and Shonka, {Nicole A} and Ganti, {Apar Kishor P}",
year = "2016",
month = "3",
day = "1",
doi = "10.1016/j.critrevonc.2015.12.006",
language = "English (US)",
volume = "99",
pages = "170--179",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - EGFR monoclonal antibodies in locally advanced head and neck squamous cell carcinoma

T2 - What is their current role?

AU - Alorabi, Mohamed

AU - Shonka, Nicole A

AU - Ganti, Apar Kishor P

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Treatment options for locally advanced squamous cell carcinoma of the head and neck (SCCHN) include either surgical resection followed by radiation or chemoradiation, or definitive chemoradiation for which single-agent cisplatin is the best studied and established. The increasing understanding of the molecular biology of SCCHN has led to an interest in the development of targeted therapies. The epidermal growth factor receptor (EGFR) is over-expressed in nearly 80-90% of cases of SCCHN and correlates with poor prognosis and resistance to radiation. Preclinical evidence showed that blocking EGFR restores radiation sensitivity and enhances cytotoxicity. This finding led to clinical trials evaluating this class of agents and the approval of cetuximab in combination with radiation for the treatment of locally advanced SCCHN. This review is focused on the anti-EGFR monoclonal antibodies and their role either with radiotherapy or chemoradiation in unresectable LA SCCHN.

AB - Treatment options for locally advanced squamous cell carcinoma of the head and neck (SCCHN) include either surgical resection followed by radiation or chemoradiation, or definitive chemoradiation for which single-agent cisplatin is the best studied and established. The increasing understanding of the molecular biology of SCCHN has led to an interest in the development of targeted therapies. The epidermal growth factor receptor (EGFR) is over-expressed in nearly 80-90% of cases of SCCHN and correlates with poor prognosis and resistance to radiation. Preclinical evidence showed that blocking EGFR restores radiation sensitivity and enhances cytotoxicity. This finding led to clinical trials evaluating this class of agents and the approval of cetuximab in combination with radiation for the treatment of locally advanced SCCHN. This review is focused on the anti-EGFR monoclonal antibodies and their role either with radiotherapy or chemoradiation in unresectable LA SCCHN.

KW - Anti-EGFR monoclonal antibodies

KW - Cetuximab

KW - Chemoradiation

KW - Locally advanced head and neck cancer

UR - http://www.scopus.com/inward/record.url?scp=84959456432&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959456432&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2015.12.006

DO - 10.1016/j.critrevonc.2015.12.006

M3 - Review article

C2 - 26797287

AN - SCOPUS:84959456432

VL - 99

SP - 170

EP - 179

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

ER -